Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Live: Live: PM inaugurates India Energy Week

Buy Sanofi India; target of Rs 8965: ICICI Direct

ICICI Direct is bullish on Sanofi India recommended buy rating on the stock with a target price of Rs 8965 in its research report dated February 24, 2022.

February 25, 2022 / 12:21 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sanofi India

Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, thrombosis, anti-infective, CNS, allergy, vitamins, minerals & supplements. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi is one of the fastest growing companies in India in anti-diabetic therapy.


Retain BUY rating on the stock due to strong chronic (anti-diabetic in particular) franchise and downsized portfolio to focus on margins Valued at Rs 8965 i.e. 30x P/E on FY24E EPS on Rs 298.9.